Amylyx Pharmaceuticals (AMLX) Non-Current Deffered Revenue (2021)
Amylyx Pharmaceuticals (AMLX) posted Non-Current Deffered Revenue of $35000.0 for Q4 2021.
Powered by 
Analysis
Amylyx Pharmaceuticals (AMLX) Non-Current Deffered Revenue (2021) Analysis & Trends
Amylyx Pharmaceuticals has reported Non-Current Deffered Revenue for 1 years, with the latest figure at $35000.0 in Q4 2021.
- On a quarterly basis, Non-Current Deffered Revenue changed N/A year-over-year to $35000.0 in Q4 2021; TTM through Dec 2021 was $35000.0, a N/A change from a year earlier, with the FY2021 full-year figure at $35000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue was $35000.0 for Q4 2021 at Amylyx Pharmaceuticals.
- The five-year high for Non-Current Deffered Revenue was $35000.0 in Q4 2021, with the low at $35000.0 in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.88 Bn | 197.89 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 181.55 Bn | 178.37 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.31 Bn | 124.45 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn | 220.40 Mn |
| 5 | Argenx Se | 61.54 Bn | 56.36 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.69 Bn | 49.55 Bn | 52.00 Mn | 147.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.07 Bn | 30.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.41 Bn | 30.12 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn | - |
| 10 | Amylyx Pharmaceuticals | 3.69 Bn | 3.69 Bn | - | - |